Compare Stocks: IZTC, TNYA, LUCD, and SPRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IZTC Invizyne Technologies	$4.00 -13.0%	$6.12	$8.50 ▼ $23.00	$25.01M	N/A	37,647 shs	24,355 shs
LUCD Lucid Diagnostics	$0.48 -8.1%	$0.83	$0.47 ▼ $1.63	$105.71M	1.12	1.90 million shs	2.33 million shs
SPRB Spruce Biosciences	$39.65 -4.4%	$51.32	$38.06 ▼ $159.41	$119.18M	3.25	85,207 shs	88,431 shs
TNYA Tenaya Therapeutics	$0.38 -6.8%	$0.64	$0.36 ▼ $2.02	$91.58M	2.87	4.19 million shs	6.81 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IZTC Invizyne Technologies	-13.04%	-24.10%	-39.16%	-33.55%	-69.21%
LUCD Lucid Diagnostics	-8.09%	-25.08%	-42.85%	-49.69%	-62.06%
SPRB Spruce Biosciences	-4.39%	-9.99%	-26.79%	-8.93%	-75.07%
TNYA Tenaya Therapeutics	-6.78%	-34.40%	-42.12%	-53.40%	-79.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IZTC Invizyne Technologies	$4.00 -13.0%	$6.12	$8.50 ▼ $23.00	$25.01M	N/A	37,647 shs	24,355 shs
LUCD Lucid Diagnostics	$0.48 -8.1%	$0.83	$0.47 ▼ $1.63	$105.71M	1.12	1.90 million shs	2.33 million shs
SPRB Spruce Biosciences	$39.65 -4.4%	$51.32	$38.06 ▼ $159.41	$119.18M	3.25	85,207 shs	88,431 shs
TNYA Tenaya Therapeutics	$0.38 -6.8%	$0.64	$0.36 ▼ $2.02	$91.58M	2.87	4.19 million shs	6.81 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IZTC Invizyne Technologies	-13.04%	-24.10%	-39.16%	-33.55%	-69.21%
LUCD Lucid Diagnostics	-8.09%	-25.08%	-42.85%	-49.69%	-62.06%
SPRB Spruce Biosciences	-4.39%	-9.99%	-26.79%	-8.93%	-75.07%
TNYA Tenaya Therapeutics	-6.78%	-34.40%	-42.12%	-53.40%	-79.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IZTC Invizyne Technologies	0.00	N/A	N/A	N/A
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	776.05% Upside
SPRB Spruce Biosciences	2.77	Moderate Buy	$158.33	299.33% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	950.70% Upside

Current Analyst Ratings Breakdown

Latest IZTC, TNYA, LUCD, and SPRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/1/2026	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/24/2026	SPRB Spruce Biosciences	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$144.00
9/18/2026	SPRB Spruce Biosciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/17/2026	SPRB Spruce Biosciences	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$149.00
9/16/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	SPRB Spruce Biosciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/18/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$123.00 ➝ $104.00
8/17/2026	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$2.50

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	$4.71M	20.63	N/A	N/A	($0.31) per share	-1.54
SPRB Spruce Biosciences	$4.91M	23.18	N/A	N/A	$39.72 per share	1.00
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.57 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
SPRB Spruce Biosciences	-$38.97M	-$39.78	N/A	N/A	N/A	N/A	-123.53%	-90.35%	11/9/2026 (Estimated)
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)

Latest IZTC, TNYA, LUCD, and SPRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	LUCD Lucid Diagnostics	-$0.04	N/A	N/A	N/A	$1.64 million	N/A
11/11/2026	Q3 2026	TNYA Tenaya Therapeutics	-$0.10	N/A	N/A	N/A	$0.80 million	N/A
11/9/2026	Q3 2026	SPRB Spruce Biosciences	-$5.6756	N/A	N/A	N/A	$50.00 million	N/A
8/12/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/12/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	-$6.68	-$0.89	-$6.68	N/A	N/A
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IZTC Invizyne Technologies	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	1.33	1.31
SPRB Spruce Biosciences	0.05	9.23	9.23
TNYA Tenaya Therapeutics	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IZTC Invizyne Technologies	N/A
LUCD Lucid Diagnostics	74.01%
SPRB Spruce Biosciences	91.71%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
IZTC Invizyne Technologies	N/A
LUCD Lucid Diagnostics	6.90%
SPRB Spruce Biosciences	4.30%
TNYA Tenaya Therapeutics	2.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IZTC Invizyne Technologies	29	6.25 million	N/A	N/A
LUCD Lucid Diagnostics	82	203.24 million	189.22 million	No Data
SPRB Spruce Biosciences	8	2.87 million	2.75 million	Optionable
TNYA Tenaya Therapeutics	70	224.23 million	218.56 million	Optionable

IZTC, TNYA, LUCD, and SPRB Headlines

Recent News About These Companies

Tenaya Therapeutics (NASDAQ:TNYA) and Sutro Biopharma (NASDAQ:STRO) Critical Contrast

October 13, 2026 | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Has Average Target Price of $4.00

September 30, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 3.2% - Here's What Happened

September 28, 2026 | marketbeat.com

Tenaya Therapeutics Announces RMAT Designation To TN-401

September 14, 2026 | rttnews.com

Tenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock Up

September 14, 2026 | rttnews.com

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...

September 14, 2026 | finance.yahoo.com

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

September 14, 2026 | globenewswire.com

Tenaya op H.C. Wainwright-conferentie: gentherapiedata

September 11, 2026 | nl.investing.com

Tenaya Therapeutics Corporate Event Calendar | NASDAQ:TNYA

September 11, 2026 | benzinga.com

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Faraz Ali Sells 22,232 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

August 18, 2026 | insidertrades.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

August 14, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

August 7, 2026 | theglobeandmail.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026 | globenewswire.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 14, 2026 | globenewswire.com

Tenaya Therapeutics (TNYA) Slides to $0.86 as Bearish Pressure Tests Support - Order Block

July 13, 2026 | donanimhaber.comD

Tenaya Names Eric Hyllengren as CFO

June 29, 2026 | marketwatch.com

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

June 29, 2026 | globenewswire.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript

June 5, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC, TNYA, LUCD, and SPRB Company Descriptions

Invizyne Technologies NASDAQ:IZTC

$4.00 -0.60 (-13.04%)

As of 10/15/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Lucid Diagnostics NASDAQ:LUCD

$0.48 -0.04 (-8.09%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$0.48 +0.00 (+0.84%)

As of 10/16/2026 07:56 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Spruce Biosciences NASDAQ:SPRB

$39.65 -1.82 (-4.39%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$39.96 +0.31 (+0.78%)

As of 10/16/2026 07:30 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Tenaya Therapeutics NASDAQ:TNYA

$0.38 -0.03 (-6.78%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+0.87%)

As of 10/16/2026 07:52 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IZTC, TNYA, LUCD, and SPRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IZTC, TNYA, LUCD, and SPRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IZTC, TNYA, LUCD, and SPRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC, TNYA, LUCD, and SPRB Company Descriptions

Invizyne Technologies NASDAQ:IZTC

Lucid Diagnostics NASDAQ:LUCD

Spruce Biosciences NASDAQ:SPRB

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IZTC, TNYA, LUCD, and SPRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IZTC, TNYA, LUCD, and SPRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IZTC, TNYA, LUCD, and SPRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC, TNYA, LUCD, and SPRB Company Descriptions

Invizyne Technologies NASDAQ:IZTC

Lucid Diagnostics NASDAQ:LUCD

Spruce Biosciences NASDAQ:SPRB

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools